News

Joint Effort to Fast-Track Diagnoses (Vienna, 21.11.2023) Partners from two EU-funded initiatives, the European Joint Program for Rare Diseases (EJPRD) and The European Rare Diseases Research Coordination and Support Action (ERICA), converged at a joint conference in Amsterdam. The joint conference of EJPRD and ERICA served as a critical platform for participants to explore and […]

CLOSER Leukemia General Assembly: Sabine Strehl presents joint work package (Vienna, 20.11.2023) Sabine Strehl from St. Anna Childrens Cancer Research Institute, recently participated in the CLOSER Leukemia General Assembly in Santiago de Chile, presenting alongside her colleagues Patricia Rubio and Maria Sara Felice from Garrahan Hospital, Buenos Aires. They shared the latest outcomes from their

VULSK Specialists Immerse in Clinical Trials Training at St. Anna CCRI under TREL Project (Vienna, 17.11.2023) The EU-funded project TREL seeks to bridge gaps in research indicators and treatment outcomes by fostering collaboration, knowledge sharing, and skill development. This week, the St. Anna Childrens Cancer Research Institute warmly welcomed three specialists from Vilnius University Hospital Santaros Klinikos (VULSK)

“Being able to laugh at yourself is a personal way of living.”  (Vienna, 24.10.2023) Comedian and artist Josef Hader in a nutshell: What he likes best about his job, why he supports St. Anna Children’s Cancer Research Institute and what else he would like to be able to do. Under the motto of our 35th

3rd School of Malignant Lymphomas in Ljubljana (Vienna, 19.10.2023) The 3rd School of Malignant Lymphomas in Ljubljana recently concluded its first day, marking a significant milestone in the field of lymphoma research and diagnostics. The event featured contributions from St. Anna CCRI’s  scientists, Margarita Maurer-Granofszky and Anna-Maria Husa, who led insightful workshops focused on high-end

Network-based approaches open a new avenue to classify and treat rare diseases Scientists at CeMM, Max Perutz Labs, and St. Anna Children’s Cancer Research Institute have achieved a significant advancement in the research of rare immune system disorders. Through a network-based approach, they have reclassified approximately 200 rare diseases. Initial comparisons with clinical data already

Childhood Cancer Awareness Month 2023 (Vienna, 01.09.2023) Throughout the year, we are committed to raising awareness about childhood cancer, which fundamentally differs from adult cancer. Every September, during Childhood Cancer Awareness Month, we think of something special to go the extra mile. This year we interviewed our young cancer researchers, delving deeper into the personal

Gene Mutation in the Immune System: Anti-Diabetes Drugs Make Immune Cells More Effective Again (Vienna, 31.08.2023) T cells are an essential component of the immune system – they fight foreign structures such as bacteria and viruses or cancer-related changes in cells. This defense reaction requires energy. Scientists led by the St. Anna Children’s Cancer Research Institute

“I think there are few things that so many people agree on as that it is good to support St. Anna CCRI!” (Vienna, 28.08.2023) “Science Buster” and molecular biologist Martin Moder in brief: Why he supports the St. Anna Children’s Cancer Research Institute, how he deals with criticism, and what he currently likes doing best!

Kaan Boztug explains defect in DOCK 11 (Vienna, 10.8.2023) Recently, Scientists from St. Anna Children’s Cancer Research Institute discovered a rare genetic defect in collaboration with the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences (ÖAW), and the Medical University of Vienna, working together with scientists from around the world. Today,

(Vienna, 9.8.2023) Scientists at St. Anna Children’s Cancer Research Institute and the Eberhard Karls University of Tübingen have shown that immunotherapy after stem cell transplantation effectively combats certain nerve tumors in children. Crucially, stem cells from a parent provide children with a new immune system that responds much better to immunotherapies. These results of an early clinical trial were published in the prestigious Journal of Clinical Oncology.

St. Anna CCRI welcomes George Cresswell as new Principal Investigator (Vienna, 01.08.2023) British bioinformatician George Cresswell has been studying various forms of childhood cancer, especially nephroblastoma, since his student days. As Principal Investigator at St. Anna Children’s Cancer Research Institute, he will turn his attention to the evolutionary biology of cancer cells in an attempt

Sarcoma Awareness Month: exposing an insidious Nemesis (Vienna, 27.07.2023) Sarcomas pose a significant challenge, especially for children and adolescents, as the tumors often go undetected and metastasize. At St. Anna Children’s Cancer Research Institute, two research groups are dedicated to studying this tumor. Sarcomas are rare forms of cancer, comprising only two percent of all

“I wish you the best of luck and groundbreaking research results!” (Vienna, 24.07.2023) Bestselling author Ursula Poznanski in brief: Why she supports the St. Anna Children’s Cancer Research Institute, how she deals with criticism, and what her best decision was! Under the motto of our 35th anniversary “Reaching for the stars”, we interviewed exciting, renowned

Successful ERNPaedCan General Assembly (Vienna, 30.06.2023) The St. Anna CCRI team, in collaboration with SIOPE, successfully coordinated this year’s General Assembly for the ERN PaedCan project, marking five years of significant achievements. The assembly functioned as platform to celebrate the progress made and to examine the benefits delivered to patients through the network’s activities. The

With a novel High-Throughput-Screening method the efficacy of numerous drugs can be tested simultaneously. Researchers are now able to quickly and efficiently assess which substances are effective against certain tumors. A team led by Martin Distel, PhD, and Sabine Taschner-Mandl, PhD, of St. Anna Children’s Cancer Research Institute has now provided the first guide on how to use this method to test the sensitivity of childhood tumors to different drugs in zebrafish models. The study was published in the Journal npj Precision Oncology.